MDMX对非小细胞肺癌放疗抵抗性的研究进展  

Progress of MDMX in the treatment of non-small cell lung cancer with radiotherapy resistance

作　　者：赵涵 黄伟 解玉卓 曾越灿[1] ZHAO Han;HUANG Wei;XIE Yu-zhuo;ZENG Yue-can(Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China)

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110022

出　　处：《实用药物与临床》2018年第3期330-332,共3页Practical Pharmacy and Clinical Remedies

基　　金：国家自然科学基金(81201803);辽宁省高等学校基本科研项目(LQNK201714)

摘　　要：肺癌是目前全球范围内最常见的恶性肿瘤之一,发病率和死亡率居各肿瘤之首。近年来,随着医疗技术的不断发展,放疗作为肺癌一种非常重要的治疗方法 ,其抵抗性的研究越来越受到关注。目前,国内外关于MDMX(Murine double minute X,又称为MDM4)对非小细胞肺癌放疗抵抗性的研究较少。本文总结近年来肺癌领域与MDMX相关的放疗抵抗机制的研究,就MDMX与非小细胞肺癌放疗抵抗性的研究进展进行综述。Lung cancer is one of the most common malignant tumors in the world,which morbidity and mortality are highest in all tumors.In recent years,with the continuous development of medical technology,radiotherapy as one of the most important treatment methods,the research on its resistivity has been paid more and more attention.So far,the research about the radiotherapy resistance of MDMX（murine double minute X,also known as MDM4） for non-small cell lung cancer is relatively rare at home and abroad.This paper summarizes the recent research related the mechanism of radiotherapy resistance of MDMX in the field of lung cancer and reviews the current progress of radiotherapy resistance of MDMX for non-small cell lung cancer.

关 键 词：MDMX 放疗抵抗性 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]